Evommune
EVMN
NYSE
IPO2025
about EVMN
Evommune is a clinical-stage biotechnology company focused on discovering and developing innovative oral and injectable therapies that target key drivers of chronic inflammatory diseases, such as urticaria, atopic dermatitis, and ulcerative colitis.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $29.52 | $33.20 | $21.80 | $535.59M | 15.95M |